Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Nothing stopped red states from "challenging the scope of FDA’s authority or its decisionmaking" before Dobbs ruling, DOJ says. "We're simply asking DOJ to step aside and let us handle ...

and it cost Pfizer $2.8 billion in pretax charges to walk away—which is rarely done when a drug has no safety or efficacy issues. So what happened? Some blame Pfizer. The firm is struggling to ...

Pfizer was founded in 1849 by two recent ... highlighting the increasing importance of legal and marketing issues over traditional R&D. He was succeeded by Ian Read and later Albert Bourla.

BMO Capital cut Terns Pharmaceuticals' price target from $26 to $15, citing costlier capital conditions despite maintaining ...

Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's ...

The Pfizer Middle East, Russia and Africa (MERA) Maternal Immunization Summit: Born Ready brought together more than 80 ...

In a landmark decision that challenges the European Commission’s transparency standards, the General Court of the European ...

For now, however, the Prevnar brand remains largely unscathed from Merck's challenge. Vaxneuvance was launched after Pfizer introduced Prevnar 20, but debuted with FDA approval for paediatric use ...

The European Court of Justice has upheld a transparency challenge over undisclosed text messages between EU Commission ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...